<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026987</url>
  </required_header>
  <id_info>
    <org_study_id>09-1824 / 201011859</org_study_id>
    <nct_id>NCT01026987</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant</brief_title>
  <official_title>A Pilot Study of G-CSF +/- Plerixafor (AMD3100) Mobilized Donor CD34+ Enriched Peripheral Blood Mononuclear Cells for the Treatment of Allogeneic Stem Cell Transplant Recipients With Limited Donor Engraftment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have not had adequate blood count recovery post related or unrelated stem cell
      transplant will be given a &quot;boost&quot; of T-cell depleted, enriched stem cells to hopefully
      improve their blood counts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have not had adequate blood count recovery post related or unrelated stem cell
      transplant will be given a &quot;boost&quot; of T-cell depleted, enriched stem cells to hopefully
      improve their blood counts.

      The unrelated donors will receive G-CSF prior to pheresis (collection of the stem cells) to
      boost the number of CD34+ cells. The related donors will receive G-CSF and AMD3100 prior to
      pheresis to boost the number of CD34+ cells. Once the CD34+ cells are collected they will be
      T-cell depleted using a cell separation device called the CliniMACS systems. The CliniMACS
      system will select the CD34+ cell and remove the T-cells. By removing the T-cells we can
      minimize the risk of Graft Versus Host Disease (GVHD). The enriched CD34+ cells will be given
      to them to hopefully give them a &quot;boost&quot; of cells that can permanently produce new blood
      cells to improve their risk of infection and bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2010</start_date>
  <completion_date type="Actual">June 8, 2016</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>100 days post CD34+ selected, T-Cell depleted transplant</time_frame>
    <description>For recipients with ANC &lt; 500 or growth factor support dependent at study entry, Time to neutrophil improvement is measured from the date of CD34+ selected, T-Cell depleted infusion to the first of 3 consecutive measurements of neutrophil count &gt; 500/μl without growth factor support for &gt;7 days prior.
RBC transfusion engraftment - independence from RBCs without growth factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to platelet engraftment</measure>
    <time_frame>100 days post CD34+ selected, T-Cell depleted transplant</time_frame>
    <description>For recipients with platelets &lt; 20,000 or platelet transfusion dependent at study entry, Time to platelet improvement is measured from the date of CD34+ selected, T-Cell depleted infusion to the of 3 consecutive measurements of platelet count ≥ 20,000/ul without platelet transfusion support for 7 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to red blood cell (RBC) improvement</measure>
    <time_frame>100 days post CD34+ selected, T-Cell depleted transplant</time_frame>
    <description>For recipients who are RBC transfusion dependent at study entry, Time to RBC improvement is measured from the date of CD34+ selected, T-Cell depleted infusion to the first date of hemoglobin &gt;9.0g/dL without &gt; 1 RBC transfusion during the previous 56 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the feasibility of collecting adequate donor CD34+ enriched T-cell depleted peripheral blood stem cells using G-CSF+ plerixafor from related donors and G-CSF alone from unrelated donors.</measure>
    <time_frame>Day 0 (transplant day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities associated with the CD34+ collection (donors)</measure>
    <time_frame>30 days post mobilization</time_frame>
    <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypically and functionally characterize donor CD34+ and donor T-cells mobilized by G-CSF from unrelated donors and mobilized with G-CSF + plerixafor from related donors.</measure>
    <time_frame>Day of mobilization (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (recipients)</measure>
    <time_frame>1 year from date of transplant</time_frame>
    <description>Overall survival is the time from the date of CD34+ selected, T-Cell depleted infusion to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute Graft vs Host Disease (GVHD)</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Incidence and severity of acute GVHD will be assessed based on the Seattle criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities associated with CD34+ cell infusion (recipients)</measure>
    <time_frame>30 days post-transplant</time_frame>
    <description>NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>1 year from date of transplant</time_frame>
    <description>Disease-Free survival is the time from the date of CD34+ selected, T-Cell depleted infusion to disease relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute Graft vs Host Disease (GVHD)</measure>
    <time_frame>2 years post-transplant</time_frame>
    <description>Incidence and severity of chronic GVHD will be assessed based on the Seattle criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of transplant-related mortality (TRM)</measure>
    <time_frame>100 days post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Stem Cell Transplant Patients</condition>
  <arm_group>
    <arm_group_label>Related Donors: G-CSF &amp; AMD3100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipient</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stem Cell Infusion on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.</description>
    <arm_group_label>Related Donors: G-CSF &amp; AMD3100</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMD3100</intervention_name>
    <arm_group_label>Related Donors: G-CSF &amp; AMD3100</arm_group_label>
    <other_name>Plerixafor</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leukapheresis</intervention_name>
    <arm_group_label>Related Donors: G-CSF &amp; AMD3100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Infusion</intervention_name>
    <arm_group_label>Recipient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Recipient

          -  Must be age ≥ 18

          -  Must have ≥90 % donor cells in the unfractionated peripheral blood based on either XY
             FISH or standard STR.

          -  More than 60 days post allogeneic stem cell transplantation.

          -  Must meet one of the following criteria:

          -  platelets &lt; 20,000 or

          -  ANC&lt;500 or

          -  transfusion dependent for at least one cell line and /or

          -  on growth factor support (G-CSF) without adequate response for 30 days and

          -  no reversible etiology found after an allogeneic stem cell transplantation

          -  Patient has an ECOG performance status of 0-2.

          -  The original stem cell donor must be available, willing, and medically able to undergo
             Mobilization and a maximum of 2 apheresis procedures

          -  Each patient (recipient) or legal guardian and donor must be willing to participate as
             a research subject and must sign an informed consent form.

        Unrelated Donors

          -  NMDP guidelines for eligibility will be followed using G-CSF alone mobilization.

        Related donors

          -  Must be ≥18 yrs old and ≤ 75 years old.

          -  Donor must be sero-negative for HIV-1&amp;2 antibody and HTLV-I&amp;II antibody, by FDA
             licensed test.

          -  Donor must have adequate renal function as defined by serum creatinine ≤ 1.5X
             institution ULN and AST and ALT ≤ 3X ULN and total bilirubin less than 2 mg/dl.

          -  Donor must be agreeable to mobilization and the second donation of PBMC.

          -  Women of child bearing potential should be willing to avoid becoming pregnant while
             receiving treatment with plerixafor.

          -  Donor must have adequate peripheral venous catheter access for leukapheresis or must
             agree to placement of a central catheter.

        Exclusion Criteria:

        Recipient

          -  Patients with confirmed relapse of their original disease

          -  Participation in other clinical trials that involve investigational drugs or devices
             except with permission from the Principal Investigator and Sponsor.

          -  Patients with documented active viral, bacterial or fungal infections.

          -  Documented allergy to murine proteins or iron dextran.

          -  Pregnancy

          -  Patients with immune mediated graft dysfunction.

        Donor

          -  Evidence of active infection at the time of study entry.

          -  Medical or physical reason which makes the donor unlikely to tolerate or cooperate
             with growth factor therapy and leukapheresis

          -  Factors which place the donor at increased risk for complications from leukapheresis
             or G-CSF therapy(e.g., autoimmune disease, multiple sclerosis, sickle cell trait,
             coronary artery disease).

          -  Pregnancy (positive serum or urine beta-HCG) or breastfeeding. Women of childbearing
             age must avoid becoming pregnant while on the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DiPersio, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

